[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598500":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":19,"collaborators":7,"id":22,"slug":7,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":25,"acronym":7,"eligibilityCriteria":26,"healthyVolunteers":23,"sex":27,"minAge":28,"maxAge":7,"enrollmentInfo":29,"targetDuration":7,"studyType":32,"phases":7,"briefSummary":33,"conditions":34,"keywords":7,"overallStatus":36,"whyStopped":7,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":7},{"fullName":5,"class":6},"The First Affiliated Hospital of Zhengzhou University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","DEB-BACE","Drug-Eluting Bead microspheres used for embolization: Drug-Eluting Bead microspheres 1tube was loaded and adsorbed chemotherapy. End point of embolization: stagnation of blood flow in tumor feeding artery",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Gang Wu","CONTACT","+86 139 3857 0175","wuganghenan2004@163.com",{"type":20,"investigatorFullName":21,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Gang Wu, MD","100598500",false,"NCT07072299","DEB-BACE for Primary Lung Cancer: A Retrospective, Single-Arm, Multicenter Study on Efficacy and Safety","Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years old, gender unrestricted; 2. Diagnosed with primary lung cancer based on the Primary Lung Cancer Diagnosis and Treatment Guidelines (2022 Edition) through histopathological examination; 3. At least one measurable lesion (evaluated according to RECIST 1.1 criteria); 4. Previously received at least one DEB-BACE treatment; 5. ECOG PS score ≤ 2; 6. Complete patient case records.\n\nExclusion Criteria:\n\n* 1\\. Presence of extensive and uncontrolled extrapulmonary brain metastasis lesions; 2. Irreversible coagulation dysfunction within a short period of time; 3. Uncontrollable hypertension, diabetes, or significant cardiovascular diseases with obvious symptoms; 4. Allergy to contrast agent; 5. Pregnant or lactating women; 6. Patients whose condition, as judged by the investigator, poses a serious threat to patient safety or hinders their participation in the study.","ALL","18 Years",{"count":30,"type":31},1213,"ESTIMATED","OBSERVATIONAL","This is a retrospective, single-arm, multicenter clinical study designed to evaluate the efficacy and safety of DEB-BACE (Drug-Eluting Bead Bronchial Artery Chemoembolization) in the treatment of primary lung cancer.",[35],"Lung Cancer Patients","NOT_YET_RECRUITING","2025-07-17",{"date":39,"type":40},"2025-07-18","ACTUAL",{"date":42,"type":31},"2025-08-01",{"date":44,"type":31},"2026-08-01",{"name":21,"class":6}]